

**MEF2C (Ser222) Antibody**  
**Rabbit Polyclonal Antibody**  
**Catalog # AN1280**

**Specification**

---

**MEF2C (Ser222) Antibody - Product Information**

Application	<b>WB</b>
Primary Accession	<a href="#">Q06413</a>
Reactivity	<b>Human</b>
Host	<b>Rabbit</b>
Clonality	<b>Polyclonal</b>
Calculated MW	<b>51221</b>

**MEF2C (Ser222) Antibody - Additional Information**

Gene ID	<b>4208</b>
Gene Name	<b>MEF2C</b>

**Target/Specificity**

Synthetic phospho-peptide corresponding to amino acid residues surrounding Ser222 conjugated to KLH

**Dilution**

WB~~ 1:1000

**Format**

Antigen Affinity Purified from Pooled Serum

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

**Precautions**

MEF2C (Ser222) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

**Shipping**

Blue Ice


**MEF2C (Ser222) Antibody - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)

- [Flow Cytometry](#)
- [Cell Culture](#)

### MEF2C (Ser222) Antibody - Images



Western blot of OCIAML2 lysate showing specific immunolabeling of the ~51 kDa MEF2C phosphorylated at Ser222 in the first lane (-). Phosphospecificity is shown in the second lane (+) where the immunolabeling is completely eliminated by blot treatment with lambda phosphatase ((λ-Ptase, 1200 units for 30 minutes).

### MEF2C (Ser222) Antibody - Background

MEF2C, also known as MADS box transcription enhancer factor 2, polypeptide C, is one of 4 MEF2 (myocyte enhancer factor 2) transcription factors that encode proteins for development of skeletal muscle and brain proliferation and differentiation (McDermott et al, 1993), along with regulating stress-response during cardiac hypertrophy in mammals (Wu et al, 2015). Phosphorylation of MEF2C at serine 59 has been shown to be negatively regulated by integrin-linked kinase (ILK) (Dong et al, 2015). Recently, high MEF2C expression has been associated with a subset of acute myeloid leukemia (AML) patients with adverse-risk disease features and poor outcomes (Laszlo et al, 2015). Phosphorylation of MEF2C at serine 222 may play a key role in MEF2C signaling.